Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Coherus Oncology (CHRS) Long-Term Debt Issuances: 2016-2024

Historic Long-Term Debt Issuances for Coherus Oncology (CHRS) over the last 1 years, with Sep 2024 value amounting to -$141,000.

  • Coherus Oncology's Long-Term Debt Issuances was N/A to -$141,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $462.7 million, marking a year-over-year change of. This contributed to the annual value of $37.0 million for FY2024, which is N/A change from last year.
  • As of Q3 2024, Coherus Oncology's Long-Term Debt Issuances stood at -$141,000, which was down 100.28% from $49.5 million recorded in Q3 2022.
  • Coherus Oncology's Long-Term Debt Issuances' 5-year high stood at $222.8 million during Q2 2020, with a 5-year trough of -$674,000 in Q3 2020.
  • Moreover, its 2-year median value for Long-Term Debt Issuances was $49.5 million (2022), whereas its average is $80.2 million.
  • Examining YoY changes over the last 5 years, Coherus Oncology's Long-Term Debt Issuances showed a top increase of 120,348.65% in 2020 and a maximum decrease of 535.85% in 2020.
  • Quarterly analysis of 4 years shows Coherus Oncology's Long-Term Debt Issuances stood at -$674,000 in 2020, then reached $222.2 million in 2021, then dropped by 13.96% to $49.5 million in 2022, then reached -$141,000 in 2024.
  • Its Long-Term Debt Issuances was -$141,000 in Q3 2024, compared to $49.5 million in Q3 2022 and $191.2 million in Q1 2022.